Postmenopausal women taking oestradiol 17-β 2 mg daily were randomized to receive either 25 or 50 µg gestodene from day 17 to 28 of the cycle in a double-blind study. Placental protein P14 (PP14) and CA 125 concentrations in uterine flushing, endometrial morphology and irregular bleeding after 12 cycles of study were observed. Eleven and 12 women in the 25 and 50 µg groups respectively completed the study. There were no significant differences in pre-treatment biochemical and morphological indices between the groups. The median PP14 concentration increased from 332 to 5800 ng/ml (P < 0.001) and from 145 to 27 160 ng/ml (P < 0.001) in the 25 and 50 µg gestodene groups respectively. No between-group significant rise of PP14 was observed. Similarly, no significant change was seen between the initial and post-treatment concentrations of CA 125 for either group. All biopsies were atrophic at inception of the study, and both regimens produced secretory endometrial transformation in the majority of biopsies. No between-group difference was observed in the morphometric indices measured, or any significant correlation between the concentrations of PP14 or CA 125 and morphology. The mean number of days of withdrawal bleeding (3.8 and 4.2 days for 25 and 50 µg respectively) were similar. In conclusion, both regimens produced a significant rise in uterine flushing concentrations of PP14, but not CA 125. PP14 is a sensitive biochemical marker in the assessment of endometrial response to hormone replacement therapy.
Introduction
In the presence of atrophic endometrium due to insufficient oestrogen priming, the addition of a progestogen may have no Although monthly withdrawal bleeding and irregular bleeding effect or render the endometrium unstable and lead to abnormal induced by conventional hormone replacement therapy (HRT) bleeding. Bleeding may also depend on the type of progestogen are important reasons why patients discontinue treatment used, as this could influence the endometrial vascular changes (Nachtigall, 1990; Okon et al., 1996) , current understanding (Casanas-Roux et al., 1996) . Levonorgestrel, in particular, may of the mechanisms underlying bleeding with HRT is limited.
have an additional effect on endometrial vasculature to produce The usual pattern of bleeding at the end of or after the well-developed arterioles and dilated sinusoids, which may progestogen phase of treatment consists of 2-4 days, although account for the higher incidence of breakthrough bleeding a median of 7 days of bleeding has been reported (Al-Azzawi with this progestogen (Graham and Fraser, 1982). et al., 1994) . Variations from this pattern may indicate pathoCurrently, the most commonly used progestogen in HRT logy, inadequate oestrogen or progestogen dose, or poor preparations is the 19-nortestosterone, norethisterone, and this compliance. Understanding of the mechanisms of bleeding has significant androgenic activity. In recent years newer during HRT use is important, as this could lead to the progestogens with less androgenic effect and with better cycle introduction of products with reduced risks of unpredictable control have been developed and used for oral contraception. bleeding which would probably induce a better acceptance of Such new progestogens include desogestrel, gestodene and HRT. In normal menstruation, two theories-vasoconstrictor norgestimate (Speroff and DeCherney, 1993) . and inflammatory-have been advanced to explain the mechanGestodene is a 19-nortestosterone progestogen that has a ism (Salamonsen et al., 1999) .
number of theoretical advantages. One of its most important Oestrogen plays the central role of priming the endometrium, and allows progesterone to exert its effects (Li et al., 1992a) .
properties is efficient cycle control. In view of its potency, lower doses will reduce androgenic activity whilst producing secretory endometrium, particularly in women with hirsutism and acne. Previous pilot safety evaluations of gestodene in postmenopausal HRT have suggested that 25 and 50 µg of gestodene in cyclical regimens for 12 days both caused a secretory endometrial transformation, without untoward changes such as endometrial hyperplasia during the period of follow-up (Schering Reports 91056, 9291 and 8946). Previous systematic clinical studies of dose-related, progesterone-related endometrial effects at constant oestrogen doses in artificial cycles showed significant differences in the mitotic activity, volume fraction of gland occupied by gland cells and volume fraction of endometrium occupied by glands, together with a significant reduction of the number of supra-and subnuclear secretory vacuoles (Li et al., 1992b) . examination of endometrial biopsy specimens using either months of amenorrhoea, with a serum FSH concentration Ͼ20 IU/l simple light microscopy or more refined histological techniques and plasma oestradiol concentration ഛ30 pmol/l, intact uterus and such as morphometry (Li et al., 1988) , histochemistry requesting HRT, were entered into this study. The women were (Klentzeris et al., 1991) , immunohistochemistry (Bell et al., recruited from among patients referred by general practitioners to the 1985) and computer-assisted three-dimensional evaluation
Jessop Hospital for Women for HRT advice. The volunteers underwent (Casanas-Roux et al., 1996) . These techniques have permitted routine blood investigations for liver and renal function and for a more detailed study of the various components of the haematological indices. Those women with abnormal results were endometrium. A recent development has been the study of excluded. The volunteers were randomized into two groups by endometrial physiology by analysis of uterine protein content computer-generated codes. Allocation of the randomization number (Li et al., 1993a) and patterns of distribution of these proteins was linked in a chronological ascending manner to the sequence of (Beier-Hellwig et al., 1989) et al., 1986; Li et al., 1993a) . Another each of the volunteers provided their informed consent before entry.
glycoprotein produced by the endometrium is CA 125 (Jacobs concentrations rise in women receiving HRT (Li et al., 1992c) , bleeding before this procedure was performed. The method previously but to date few data are available regarding the concentrations described (Okon et al., 1998) In addition, the morphometric and biochemical changes were was inserted into the vagina, exposing the cervix, which was then compared to determine how well the changes correlated to each cleaned with Savlon. A Pipelle endometrial sampler that had been other. This study formed part of a double-blind, multicentre trial preloaded with 1 ml of sterile physiological saline (0.9% NaCl) was evaluating the safety of 25 and 50 µg gestodene in combination slowly introduced into the uterus. After about 30 s, the tip of the with 2 mg oestradiol-17β as a novel HRT; however, the data sampler was withdrawn by about 2 cm into the lower part of the uterine cavity, after which the saline solution was aspirated slowly on PP14 and CA 125 were collected only at this centre.
through the vacuum mechanism of the Pipelle sampler. The plunger was withdrawn in increments of~2 cm over a period of~30 s. A
Materials and methods
volume of between 0.8 and 1 ml was consistently aspirated. The Subjects aspirate was immediately centrifuged at 2200 g for 5 min and the supernatant stored at -20°C at the Biomedical Research Unit at the Thirty-three postmenopausal women, defined as those women under 65 years of age who had a minimum of 12 and a maximum of 72
Jessop Hospital for Women, for assay of PP14 and CA 125. for processing and analysis. The fixed tissue was embedded in paraffin BMI ϭ body mass index.
Endometrial biopsy and morphology
wax and stained with haematoxylin and eosin before being sectioned for examination by light microscopy. The endometrial biopsies were examined histologically using published dating criteria (Noyes et al., and CA 125 and the morphometric indices in the groups were 1950) and morphometric analysis (Li et al., 1988) . The main reasons given for withdrawal were hormone-related fields were examined from each slide.
side effects such as retention of fluid, weight gain, depression and breast tenderness. None of the women withdrew for PP14 assay bleeding problems, although this occurred in the other centres PP14 was measured by radioimmunoassay using the method described previously (Bolton et al., 1987) . PP14 was iodinated by the chlorabased in the UK, Germany, Belgium, the Republic of Ireland mine-T method, and the resulting tracer was purified using a column and The Netherlands. Of the 23 women left in the study in of ConA Sepharose. For the assay, 100 µl of 1 ng/ml PP14 tracer the first year, 11 were in the 25 µg group and 12 in the 50 µg and 100 µl of standards or sample were incubated at room temperature gestodene treatment group. Two groups were identified for for 24 h with 100 µl antiserum, at a dilution to bind 45% of the analysis on the basis of the dose of gestodene in the preparation. (Table I ). There was no significant difference in the groups sensitivity of the assay was 3 ng/ml, and the intra-and inter-assay for age, body mass index or interval from the menopause. coefficients of variation were below 10% at a concentration of 3 ng/ml. Figure 2 (box-plot) shows the concentrations of PP14 in uterine CA 125 concentrations in serum and uterine flushing were measured flushing at inception and after 12 months of study HRT. In at the Immunology Department of the Northern General Hospital, the 25 µg gestodene group there was a significant increase in Sheffield using an enzyme-linked immunosorbent assay (ELISA)-CA 125 11 kit (CIS Bio International, Cedex, France), which is a twothe median concentration of PP14 from a pre-treatment value site immunoradiometric assay. The CA 125 was adsorbed onto the of 332 ng/ml to 5800 ng/ml after treatment (P Ͻ 0.001).
Biochemistry

CA 125 assay
solid phase by antibody ELISA-CA 125 11 and then quantified using Similarly, in the 50 µg gestodene group, there was a significant radioiodinated OC125 antibody as tracer. All assays were carried rise in median concentration from 145 ng/ml pre-treatment to out in duplicate and performed according to the manufacturer's 27 160 g/ml after treatment (P Ͻ 0.001). The median uterine instructions. The lower and upper limits of detection were 0.5 and flushing PP14 concentration was increased 30-fold, from 304 500 IU/ml respectively, and the inter-and intra-assay coefficients of ng/ml before study to 8950 ng/ml after treatment. However, variation were Ͻ5% at these concentrations.
there was no significant difference in the rise in PP14 concentration between subjects in the 25 and 50 µg gestodene groups.
Study follow-up and menstrual calendar
The pre-treatment median serum concentration of PP14 in
The volunteers were requested to record tablet taking and bleeding the 25 µg gestodene group was 11.7 ng/ml, and this rose to (if any) on a daily basis on a diary card provided. The women were 20.1 ng/ml after 1 year of treatment (P Ͻ 0.05). However, in reviewed every 3 months, and at the end of each 12 months the the 50 µg gestodene group, the increase in median serum PP14 uterine flushing and the endometrial biopsy were repeated and analysis concentration was not significant (from 14.0 to 15.6 ng/ml). performed as described previously.
A comparison of the treated groups showed no significant difference in serum PP14 concentrations between those subjects Analysis of data receiving 25 or 50 µg gestodene.
In view of the variability in concentrations of PP14 and CA 125, the data were log transformed before analysis. Concentrations of PP14
The median serum concentrations of CA 125 pre and post the 50 µg gestodene group were 15.5 and 14.0 IU/l. There was no significant change in post-treatment plasma concentrations of CA 125 within either group, or between the treatment gestodene was 3.8 days, while that for women taking 50 µg was 4.2 days. There was no statistically significant difference groups. The median uterine flushing concentrations of CA 125 pre and post 12 cycles of treatment in the 25 µg gestodene between the two groups. Most of the bleeding occurred between day 28 and day 4 of the subsequent cycle. One subject who group were 45 600 and 41 360 IU/l respectively. No significant rise was observed between the pre-and post-treatment uterine was taking the 25 µg preparation experienced an episode of irregular bleeding that occurred within the first 6 months of flushing concentrations of CA 125 in either the 25 or 50 µg gestodene groups, or between treatment groups. the trial. The overall multicentre regular or no bleeding was 80% for 25 µg gestodene and 74% for 50 µg, whilst the rest Bleeding patterns were irregular for each group. Vaginal bleeding was defined as any appearance of blood in Endometrial morphology the vagina (regardless of amount), or any requirement for sanitary towels. Bleeding during treatment with HRT was
The response of the endometrium was assessed using published criteria (Noyes et al., 1950) (Table II) and seven morphometric classified as light (less than bleeding associated with normal menstruation), moderate (like normal menstruation) and heavy indices (Johannisson et al., 1982; Li et al., 1987) . Atrophy was observed in all subjects at the inception of the study. (more than normal menstruation). Bleeding was regular if it occurred between day 23 of the current cycle and day 4 of Insufficient tissue was obtained for analysis in three women at the end of the 12th cycle (in one woman in the 25 µg group, the subsequent cycle, and irregular for all other episodes of vaginal bleeding with or without regular bleeding. Bleeding and in two women in the 50 µg gestodene groups). There was secretory transformation of the endometrium in the majority data were not complete for two women in the 50 µg group; hence these were excluded from the analysis. The nature of of biopsies from both treatment groups. The mean (Ϯ SD) glandular secretory activity was 1.0 Ϯ bleeding before the menopause was based on patient recall. On average, bleeding was light to normal in the two groups 0.4 for the 25 µg gestodene and 0.9 Ϯ 0.5 for the 50 µg.
There was no statistically significant difference in gland of HRT regimen compared with the nature of bleeding before the menopause. There was no difference in the pattern of secretory activity between the two groups. Similarly, there was no difference in other morphometric indices in the two groups bleeding between the two preparations. Figure 3 shows the pattern of menstruation in women taking (Table III) . Comparison of the morphometric indices on treatment showed no significant difference in endometrial response 25 and 50 µg gestodene HRT preparations. The mean number of days of withdrawal bleeding in women taking 25 µg between those on 25 µg gestodene and those on 50 µg, using Values are median (mean Ϯ SD). vv:G/E ϭ ratio of gland to endometrium; vv:GC/G ϭ ratio of gland cell to gland. NS ϭ no statistically significant difference.
the specified morphometric indices. Moreover, there were no vidual variations in the spectrum of oestrogenic, androgenic, features of endometrial hyperplasia in any of the samples over antioestrogenic, glucocorticoid and the antimineralocorticoid the study period. Neither were there any features of endometrial effects of gestodene (Edgren, 1986) may have affected the hyperplasia in any of the samples studied, which suggests that PP14 concentrations. This difference in bioavailability at the both regimens are protective over the 12-cycle period studied.
endometrial level, though not reflected in the histological No statistical correlation was observed between the biochemical biopsies, may account for the observed variation in uterine markers and the morphological indices.
washing concentrations of PP14. To what extent these variations in endometrial level bioavailability and receptor-mediated responses affect endometrial PP14 production and Discussion secretion are speculative. Finally, it is possible that the postOestrogen monotherapy has been shown to be associated with menopausal endometrial secretory response may vary among an increased incidence of endometrial hyperplasia, and also women. It could be argued that the sampling technique could an increased risk of endometrial carcinoma. The addition of introduce this variation, but there was no change either in progestogen to oestrogen therapy has succeeded in reducing technique or in the person taking the samples (M.A.O.). There the risks of endometrial cancer (Sturdee et al., 1994; Lobo, was no correlation between the pattern of bleeding and the 1995), which can remain elevated for a decade after cessation of concentrations of PP14 in the uterine washings, and this is HRT (Green et al., 1996) . In the current study the biochemical consistent with our previous findings (Okon et al., 1998) and markers PP14 and CA 125 and endometrial morphometry were those of others (Habiba and Al-Azzawi, 1994 ). used to compare the response of the endometrium to two There was no significant change in the concentration of CA regimens of oestradiol/gestodene combination in postmeno-125 in uterine flushing during treatment. This supports earlier pausal women. Although these two proteins have been studied findings that there was no significant variation in the uterine extensively, their use as markers of endometrial status in flushing concentrations of this protein either during the menpostmenopausal women has not been fully elucidated. Previstrual cycle or during treatment with two different forms of ously, it has been observed that PP14 concentrations in the period-free HRT (Okon et al., 1998) . endometrial fluid are reduced in postmenopausal women, and that endometrial CA 125 appears to be independent of menMorphology strual status (unpublished data). It has also been reported that On the basis of the current results, no significant difference was measurement of PP14 concentrations in uterine flushings may observed between the various morphological measurements in enable the different effects of various forms of HRT on the 25 and 50 µg gestodene groups, with both regimens endometrial function to be determined (Okon et al., 1998) .
producing secretory transformation in the majority of biopsies.
Biochemistry
First, the differences in the endometrium constitute a spectrum, the elements blend very closely and may be difficult to In the current study, the uterine flushing concentrations of discern. However, the chances of error were reduced by the PP14 appear to show significantly greater variability than were use of the theoretically objective method of morphometric observed in previous studies using period-free preparations analysis. Nonetheless, to demonstrate a significant difference, (Okon et al., 1998) . The reason for this variability may be the use of this method in a small number of patients requires measurement error, but this is unlikely as the PP14 assay was it to be further improved. The only limitation of the observation performed in paired samples. A more likely reason is the is the fact that a relatively small number of biopsies were considerable inter-subject variations in pharmacokinetics for studied (10 in each group). However, it is still possible that synthetic progestational compounds such as gestodene. Third, there is indeed a difference between the two groups, which there may be a difference in the pharmacokinetics of the concurrently administered oestradiol 17β. Additionally, indicould be detected by a larger sample size; however, the
